The global anticoagulants market size is projected to reach 45.50 billion by the end of 2026. According to a report published by Fortune Business Insights, titled “Anticoagulants Market Size, Share & Industry Analysis, By Disease Indication (Pulmonary Embolism (PE), Deep Vein) Thrombosis (DVT), Atrial Fibrillation, Heart Attacks, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026, ”the market was worth USD 21.45 billion in 2018 and will exhibit a CAGR of 9.9% during the forecast period, 2019-2026.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/anticoagulants-market-101807

Some of the leading companies that are operating in the global market are:

Bristol-Myers Squibb Company
Pfizer Inc.
Bayer AG
Janssen Pharmaceuticals, Inc.
Eisai Co., Ltd.
Other Prominent Players
Key Industry Developments:

February 2019: Novartis AG and Blackstone's Life Sciences announced the launch of Anthos Therapeutics, a product aimed at the development of new and pipeline drugs that are polyclonal of anticoagulants.

October 2019: Janssen Pharmaceuticals received approval from the US Food and Drug Administration for usage of Riveraxoban, a drug aimed at the treatment of thromboembolic complications.

The report offers insights into the latest anticoagulants market trends. It highlights leading companies in the market and discusses the strategies that these companies have adopted in recent years. Forecast values ​​of the market have been provided for the period of 2019-2026. The market has been segmented on the basis of several criteria including route of administration, distribution type, and disease indication. Factual figures have been evaluated through trusted sources. Other forecast valued have been gathered through interviews and opinions of experienced market research professionals.